The word “adaptogen” belongs to twentieth-century pharmacology, not to classical Ayurvedic terminology. The European Medicines Agency traces it to the Soviet pharmacologist N. V. Lazarev in 1947. Rasayana is a broader Ayurvedic approach associated with nourishment, strength, longevity, mental function, and resilience. The Ayurvedic Pharmacopoeia of India (API) classifies Ashwagandha and Brahmi as Rasayana drugs, but Rasayana is not an exact synonym for adaptogen. Ashwagandha is the dried mature root of Withania somnifera (L.) Dunal, family Solanaceae. Brahmi is the dried whole plant of Bacopa monnieri (L.) Wettst., currently placed in Plantaginaceae; the API uses the older family name Scrophulariaceae.

Adaptogen and Rasayana: Related but Distinct

Later descriptions of adaptogens commonly emphasize relative safety at ordinary doses, increased resistance to different stressors, and a normalizing influence on disturbed function. These criteria do not require one universal molecular pathway. Human outcomes and biomarkers must also be distinguished from animal, cell, and purified-compound experiments.

  • Human evidence: validated stress, attention, memory, cortisol, or acetylcholinesterase measurements in controlled trials.
  • Preclinical evidence: effects on NF-kB, Nrf2, heat-shock proteins, neurite growth, antioxidant systems, or neurotransmission in experimental models.
  • Product relevance: findings from an isolated constituent or one standardized extract do not automatically apply to every powder or commercial preparation.

Ashwagandha (Withania somnifera): Root Rasayana

The API describes Ashwagandha as Tikta and Kashaya in rasa, Laghu in guna, Ushna in virya, and Madhura in vipaka. Its listed actions include Rasayana, Balya, Vajikarana, and Vata-Kaphahara. The adult powder dose is 3–6 g, with traditional uses including daurbalya, kshaya, shotha, vataroga, and klaibya. These indications belong to Ayurvedic diagnosis and should not be converted directly into modern disease claims.

The API identifies alkaloids and withanolides among the root’s constituents. Withanolides are steroidal lactones, but their proportions vary by plant part, extraction method, and product. Withaferin A is frequently used in laboratory experiments; its effects cannot be treated as the proven clinical mechanism of every Ashwagandha root preparation.

In a 2012 randomized, double-blind, placebo-controlled trial, 64 adults with chronic stress received a high-concentration full-spectrum root extract at 300 mg twice daily or placebo for 60 days. The extract group had larger improvements in stress scores and serum cortisol. The result applies most directly to that extract, population, and duration rather than establishing a universal dose.

Mechanistic findings are mainly preclinical. Withaferin A has interacted with Cys179 of IKK-beta and inhibited NF-kB signaling in biochemical and cellular work. Cell experiments have linked it with HSP70-related responses, while animal and cell models have examined Nrf2-dependent protection. Withanolide A has promoted neurite regeneration in experimental models. These findings do not establish Ashwagandha as a treatment for Alzheimer’s or Parkinson’s disease.

Brahmi (Bacopa monnieri): Medhya Rasayana

The API defines Brahmi as the dried whole plant. Its profile is Madhura, Tikta, and Kashaya in rasa; Laghu and Sara in guna; Shita in virya; and Madhura in vipaka. Listed actions include Medhya, Rasayana, Vatahara, Kaphahara, Ayushya, and Matiprada. The adult powder dose is 1–3 g, and formulations include Brahmi Ghrita and Sarasvatarishta. Botanical identification matters because “Brahmi” is also used regionally for other plants.

Bacopa contains dammarane-type triterpenoid saponins grouped as bacosides. Bacoside A is a mixture that can include bacoside A3 and related saponins, not a single uniform molecule in ordinary extract literature. Products differ in assay method and total saponin or bacoside content, so equal milligram doses may not be equivalent.

A 2014 meta-analysis identified nine randomized controlled trials involving 518 participants and evaluated standardized Bacopa extracts taken for at least 12 weeks. The pooled analysis indicated potential cognitive benefit, particularly for speed of attention. An earlier systematic review found the most consistent effects in memory-related outcomes after chronic administration.

In a 12-week randomized, double-blind trial of 60 healthy older adults, 300 or 600 mg daily of a specific extract improved several working-memory, attention, and cognitive-processing measures and reduced plasma acetylcholinesterase activity. This biomarker is compatible with cholinergic involvement, but it does not prove a single clinical mechanism. Antioxidant, synaptic, and neuroprotective actions remain principally preclinical.

Comparative Evidence Table

Ashwagandha and Brahmi overlap as Rasayana drugs but differ in official plant part, Ayurvedic profile, clinical emphasis, and the strength of mechanistic support.

Topic Ashwagandha Brahmi Evidence level
Official drug Dried mature root Dried whole plant API monographs
Ayurvedic actions Rasayana, Balya, Vajikarana, Vata-Kaphahara Medhya, Rasayana, Vatahara, Kaphahara, Ayushya, Matiprada API monographs
Controlled human findings Stress scores and serum cortisol with one root extract over 60 days Selected attention and memory outcomes during chronic use PMIDs 23439798, 23320031, 24252493
Human biomarker Serum cortisol Plasma acetylcholinesterase activity Trial-specific, not universal mechanisms
Preclinical pathways IKK-beta/NF-kB, HSP70, Nrf2, neurite growth Cholinergic, antioxidant, synaptic, and neuroprotective effects Biochemical, cell, or animal models

Evidence Map

The infographic separates pharmacopoeial identity, controlled human findings, and laboratory mechanisms.

ASHWAGANDHA AND BRAHMI: EVIDENCE LAYERS
ASHWAGANDHA ROOT
API: Rasayana, Balya, Vajikarana
Human: stress scores and cortisol
Preclinical: NF-kB, HSP70, Nrf2

BRAHMI WHOLE PLANT
API: Medhya and Rasayana
Human: attention and memory
Preclinical: cholinergic and antioxidant

Safety and Clinical Use

Pharmacopoeial powder doses and concentrated-extract doses are not interchangeable. Ashwagandha appears generally well tolerated during short-term use, commonly up to about three months, but can cause stomach upset, loose stools, nausea, or drowsiness. Rare cases of clinically apparent liver injury have been reported. It should be avoided during pregnancy, and medical supervision is important with liver, thyroid, or autoimmune conditions and when medicines are used. The Ministry of AYUSH advises against substituting Ashwagandha leaves for the pharmacopoeial root in Ayurvedic, Siddha, or Unani formulations.

Brahmi commonly causes gastrointestinal effects such as nausea, abdominal cramping, or increased stool frequency. Safety in pregnancy, breastfeeding, childhood, prolonged use, or use with multiple medicines should not be inferred from short adult trials. Consult a qualified Ayurvedic practitioner and healthcare provider before using either medicine for persistent symptoms or alongside treatment. Seek prompt care for jaundice, dark urine, severe vomiting, marked drowsiness, rash, breathing difficulty, or another significant reaction.

Conclusion

Ashwagandha root and Brahmi whole plant are established Rasayana drugs with different Ayurvedic profiles. Human trials support stress-related outcomes for particular Ashwagandha extracts and selected attention or memory outcomes during chronic Bacopa use. Laboratory findings involving withanolides, NF-kB, HSP70, Nrf2, acetylcholinesterase, and neural pathways provide hypotheses rather than universally proven clinical mechanisms. Selection and dosing should follow authenticated plant identity, preparation, individual assessment, and professional guidance rather than treating the herbs as a universal “adaptogen stack.”

References

  1. Ema (ema.europa.eu)
  2. Powo (powo.science.kew.org)
  3. Powo (powo.science.kew.org)
  4. Ayurvedic Pharmacopoeia of India
  5. Ayurvedic Pharmacopoeia of India
  6. Ministry of AYUSH
  7. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults (2012), PubMed Central
  8. Withaferin A inhibits NF-kappaB activation by targeting cysteine 179 in IKKβ (2014), PubMed
  9. Withaferin A Induces Heat Shock Response and Ameliorates Disease Progression in a Mouse Model of Huntington’s Disease (2021), PubMed
  10. Withaferin A induces Nrf2-dependent protection against liver injury: Role of Keap1-independent mechanisms (2016), PubMed Central
  11. Neuritic regeneration and synaptic reconstruction induced by withanolide A (2005), PubMed
  12. In Silico and In Vitro Analysis of Bacoside A Aglycones and Its Derivatives as the Constituents Responsible for the Cognitive Effects of Bacopa monnieri (2015), PubMed
  13. Bacoside A3–a triterpenoid saponin from Bacopa monniera (1994), PubMed
  14. Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract (2014), PubMed
  15. The cognitive-enhancing effects of Bacopa monnieri: a systematic review of randomized, controlled human clinical trials (2012), PubMed
  16. Effects of 12-Week Bacopa monnieri Consumption on Attention, Cognitive Processing, Working Memory, and Functions of Both Cholinergic and Monoaminergic Systems in Healthy Elderly Volunteers (2012), PubMed
  17. NCCIH
  18. NCBI
  19. NCBI